96 related articles for article (PubMed ID: 29355559)
1. Evaluation of pharmacokinetics/pharmacodynamics and efficacy of one-month depots of TAK-448 and TAK-683, investigational kisspeptin analogs, in male rats and an androgen-dependent prostate cancer model.
Tanaka A; Nakata D; Masaki T; Kusaka M; Watanabe T; Matsui H
Eur J Pharmacol; 2018 Mar; 822():138-146. PubMed ID: 29355559
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of pharmacokinetic/efficacy analysis of an investigational kisspeptin analog, TAK-448, in quantitatively evaluating anti-tumor growth effect in the rat VCaP androgen-sensitive prostate cancer model.
Ishikawa K; Tanaka A; Kogame A; Watanabe T; Tagawa Y; Matsui H
Eur J Pharmacol; 2018 Jun; 828():126-134. PubMed ID: 29580912
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolide.
Matsui H; Masaki T; Akinaga Y; Kiba A; Takatsu Y; Nakata D; Tanaka A; Ban J; Matsumoto S; Kumano S; Suzuki A; Ikeda Y; Yamaguchi M; Watanabe T; Ohtaki T; Kusaka M
Eur J Pharmacol; 2014 Jul; 735():77-85. PubMed ID: 24747751
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic modeling of the metastin/kisspeptin analog, TAK-448, for its anti-tumor efficacy in a rat xenograft model.
Kogame A; Ishikawa K; DeJongh J; Tagawa Y; Matsui H; Moriya Y; Kondo T; Asahi S
Biopharm Drug Dispos; 2020 Jul; 41(7):283-294. PubMed ID: 32562504
[TBL] [Abstract][Full Text] [Related]
5. Sustained exposure to the investigational Kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: results from two phase 1 studies.
MacLean DB; Matsui H; Suri A; Neuwirth R; Colombel M
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1445-53. PubMed ID: 24762108
[TBL] [Abstract][Full Text] [Related]
6. Additive effect of simultaneous continuous administration of degarelix and TAK-448 on LH suppression in a castrated rat model.
Stalewski J; Hargrove DM; Wolfe M; Kohout TA; Kamal A
Eur J Pharmacol; 2018 Apr; 824():24-29. PubMed ID: 29378196
[TBL] [Abstract][Full Text] [Related]
7. Chronic administration of the metastin/kisspeptin analog KISS1-305 or the investigational agent TAK-448 suppresses hypothalamic pituitary gonadal function and depletes plasma testosterone in adult male rats.
Matsui H; Tanaka A; Yokoyama K; Takatsu Y; Ishikawa K; Asami T; Nishizawa N; Suzuki A; Kumano S; Terada M; Kusaka M; Kitada C; Ohtaki T
Endocrinology; 2012 Nov; 153(11):5297-308. PubMed ID: 23027808
[TBL] [Abstract][Full Text] [Related]
8. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
[TBL] [Abstract][Full Text] [Related]
9. The Enhancement of Subcutaneous First-Pass Metabolism Causes Nonlinear Pharmacokinetics of TAK-448 after a Single Subcutaneous Administration to Rats.
Moriya Y; Kogame A; Tagawa Y; Morohashi A; Kondo T; Asahi S; Benet LZ
Drug Metab Dispos; 2019 Sep; 47(9):1004-1012. PubMed ID: 31201213
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-683, an investigational metastin analogue in healthy men.
Scott G; Ahmad I; Howard K; MacLean D; Oliva C; Warrington S; Wilbraham D; Worthington P
Br J Clin Pharmacol; 2013 Feb; 75(2):381-91. PubMed ID: 22803642
[TBL] [Abstract][Full Text] [Related]
11. Investigation of disposition for TAK-448, a synthetic peptide of kisspeptin analog, in rats and dogs using the radiolabeled TAK-448 suitable for pharmacokinetic study.
Moriya Y; Kogame A; Tagawa Y; Morohashi A; Kondo T; Asahi S
Xenobiotica; 2019 Jul; 49(7):833-839. PubMed ID: 30044673
[TBL] [Abstract][Full Text] [Related]
12. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.
Nagasawa J; Mizokami A; Koshida K; Yoshida S; Naito K; Namiki M
Int J Urol; 2006 May; 13(5):587-92. PubMed ID: 16771730
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats.
Lee DS; Kim SJ; Choi GW; Lee YB; Cho HY
Molecules; 2018 Apr; 23(4):. PubMed ID: 29662027
[TBL] [Abstract][Full Text] [Related]
14. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
15. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
[TBL] [Abstract][Full Text] [Related]
16. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
[TBL] [Abstract][Full Text] [Related]
17. Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats.
Hara T; Kouno J; Kaku T; Takeuchi T; Kusaka M; Tasaka A; Yamaoka M
J Steroid Biochem Mol Biol; 2013 Mar; 134():80-91. PubMed ID: 23146910
[TBL] [Abstract][Full Text] [Related]
18. [A phase II pharmacological study of leuprolide acetate 6-month depot, TAP-144-SR (6M), in treatment-Nazve patients with prostatic cancer who received a single subcutaneous or intramuscular injection].
Komura E; Fujimoto T; Takabayashi N; Okamoto H; Akaza H
Gan To Kagaku Ryoho; 2014 May; 41(5):587-93. PubMed ID: 24917003
[TBL] [Abstract][Full Text] [Related]
19. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of sensitive sandwich ELISAs for two investigational nonapeptide metastin receptor agonists, TAK-448 and TAK-683.
Yoshida N; Nishizawa N; Matsui H; Moriya Y; Kitada C; Asami T; Matsumoto H
J Pharm Biomed Anal; 2012 Nov; 70():369-77. PubMed ID: 22748666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
